Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care
{{output}}
BackgroundPomalidomide (POM) can cause skin rash, although it is generally considered less frequent than lenalidomide (LEN)-induced rash. However, skin rash remains a clinically relevant adverse event that may lead to treatment interruption in patients with mu... ...
